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Context: Telomerase promoter mutations (TERT) were recently described in follicular cell-derived
thyroid carcinomas (FCDTC) and seem to be more prevalent in aggressive cancers.
Objectives:Weaimed toevaluate the frequencyofTERTpromotermutations in thyroid lesions and
to investigate the prognostic significance of such mutations in a large cohort of patients with
differentiated thyroid carcinomas (DTCs).
Design: This was a retrospective observational study.
Setting and Patients:We studied 647 tumors and tumor-like lesions. A total of 469 patients with
FCDTC treated and followed in five university hospitals were included. Mean follow-up (SD) was
7.8  5.8 years.
Main Outcome Measures: Predictive value of TERT promoter mutations for distant metastasiza-
tion, disease persistence at the end of follow-up, and disease-specific mortality.
Results: TERT promoter mutations were found in 7.5% of papillary carcinomas (PTCs), 17.1% of
follicular carcinomas, 29.0% of poorly differentiated carcinomas, and 33.3% of anaplastic thyroid
carcinomas. Patients with TERT-mutated tumors were older (P .001) and had larger tumors (P
.002). In DTCs, TERTpromotermutationswere significantly associatedwith distantmetastases (P
.001) and higher stage (P  .001). Patients with DTC harboring TERT promoter mutations were
submitted to more radioiodine treatments (P  .009) with higher cumulative dose (P  .004) and
tomore treatmentmodalities (P .001).At theendof follow-up,patientswithTERT-mutatedDTCs
weremoreprone tohavepersistent disease (P .001).TERTpromotermutationswere significantly
associated with disease-specific mortality [in the whole FCDTC (P .001)] in DTCs (P .001), PTCs
(P  .001), and follicular carcinomas (P  .001). After adjusting for age at diagnosis and gender,
the hazard ratio was 10.35 (95% confidence interval 2.01–53.24; P .005) in DTC and 23.81 (95%
confidence interval 1.36–415.76; P  .03) in PTCs.
Conclusions: TERT promoter mutations are an indicator of clinically aggressive tumors, being
correlated with worse outcome and disease-specific mortality in DTC. TERT promoter mutations
have an independent prognostic value in DTC and, notably, in PTC. (J Clin Endocrinol Metab 99:
E754–E765, 2014)
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Telomerase activation is known to be a hallmark of can-cer (1), being detected in up to 80% of malignant
tumors (2, 3). Some tumors may maintain their telomeres
by an alternative mechanism, which is telomerase inde-
pendent, designated as alternative lengthening of telo-
meres, which appears to maintain telomeres through
recombination-based interchromosomal exchange of se-
quence information (4, 5). The maintenance of telomere
length in cancer cells is thought to result more frequently
from telomerase reexpression than from alternative
lengthening of telomeres, although the mechanisms un-
derlying such process remain largely unknown.
Thyroid tissue is a conditionally renewing tissue,which
proliferates rarely in adult life (6). We have proposed that
the embryonic remnants of the ultimobranchial body, the
so-called solid cell nests of the thyroid, may represent the
pool of thyroid stem cells because they express several
stem cell markers, including telomerase (7). At variance
with this, normal thyroid tissue is thought tobe telomerase
negative, thus raising the possibility that the reactivation
of telomerase may be a useful marker of tumor develop-
ment (8).
Several studies have examined telomerase activity in
thyroid lesions and surrounding normal tissues using a
PCR-based telomeric repeat amplification protocol assay
for detection of telomerase activity and RT-PCR or quan-
titative real-time RT-PCR for the detection of TERT
mRNA (for a review see reference 9). Thyroid carcinomas
apparently display less frequent telomerase activation
than other human carcinomas. Approximately 66%of all
the thyroid carcinomas analyzed to date display telomer-
ase activation that is more frequent in undifferentiated
thyroid carcinomas than in differentiated carcinomas (9).
Putting together the results obtained in the evaluation of
telomerase activity by several authors, telomerase activity/
expression is reported in 48% of papillary thyroid carci-
nomas (PTCs) and 71% of follicular thyroid carcinomas
(FTCs).TERT copynumber gainwas described in familial
PTCs (10). Capezzone et al (11) observed telomerase ac-
tivity in most sporadic and familial malignant thyroid tu-
mors as well as in some adenomas. No telomerase activity
was observed in hyperplastic nodules or in normal thyroid
tissue of patients with sporadic PTCs (11). Altogether, the
aforementioned findings suggest that telomerase activity
may contribute to a more aggressive behavior of thyroid
tumors (12–14).
Recently highly frequent mutations in the promoter re-
gion of TERTwere reported in melanomas, gliomas, and
bladder and thyroid cancers (15–18). Thesemutations oc-
cur in two hot spot positions, located124 and146 bp
upstream from the ATG start site (124GA and
146GA, CT on the opposite strand) and confer en-
hanced TERT promoter activity (1, 2) putatively by gen-
erating a consensus binding site (GGAA) for ETS tran-
scription factors within the TERT promoter region. In
thyroid tumors, these mutations were shown to be asso-
ciated with aggressive features and with the presence of
BRAF or BRAF/RAS mutations (15, 19, 20). The role
played byTERTpromotermutations in the clinical course
of thyroid tumors, response to the therapy and survival of
cancer patients, remains to be addressed.
In the present study, we searched for the presence of
telomerase promotermutations in a large series of thyroid
tumors and investigated the putative clinical significance
of such somatic alterations.
Materials and Methods
All the procedures described in this study were in accordance
with national and institutional ethical standards. Patients signed
an informed consent form approved by the internal reviewing
board.
Patient tissue samples
Six hundred forty-seven formalin-fixed, paraffin-embedded
tissue samples from tumors and tumor-like lesions of the thyroid
and from normal thyroid parenchyma localized at distance from
the respective tumorswere collected from the files of the Institute
of Molecular Pathology and Immunology of the University of
Porto (Porto, Portugal), corresponding topatients followedup in
five university hospitals in Portugal and Spain. The histology of
all tumor samples was revised by three pathologists (C.E.,
J.M.C.-T.,M.S.-S.) according to theWorldHealthOrganization
criteria (21). Data on the histological characteristics of the 647
samples and the frequency of TERT promoter mutations in
each group are summarized in Supplemental Table 1, pub-
lished on The Endocrine Society’s Journals Online web site at
http://jcem.endojournals.org. Twelve follicular adenomas
Institute of Molecular Pathology and Immunology of the University of Porto (M.Me., A.G.d.R., J.V., R.B., J.P., C.T., R.C., A.A., C.S., C.E., P.C., H.P., J.L., V.M., M.S.-S., P.S.), 4200-465
Porto, Portugal; Medical Faculty, University of Porto (A.G.d.R., C.T.), 4200-139 Porto, Portugal; Institute of Biomedical Sciences of Abel Salazar, University of Porto (J.V., A.A.), 4050-313
Porto, Portugal; Department of Pathology andOncology,Medical Faculty, University of Porto (J.L., V.M.,M.S.-S., P.S.), 4200-139 Porto, Portugal; Departments of Endocrinology, Diabetes,
and Metabolism (M.Me., F.C., M.C.) and Pathology (M.J.M.), University and Hospital Center of Coimbra, 3000-075 Coimbra, Portugal; Unit of Endocrinology (M.Me., M.C.), Faculty of
Medicine, University of Coimbra, 3000-548 Coimbra, Portugal; School of Allied Health Sciences, ESTSP - Escola Superior de Tecnologia da Saúde do Porto (R.C.), Polytechnic of Porto,
4400-330 Vila Nova de Gaia, Portugal; Portuguese Institute of Oncology (H.P.), Coimbra Center, 3000-075 Coimbra, Portugal; Department of Pathology (T.A.), Hospital Pedro Hispano,
4464-513 Matosinhos, Portugal; Department of Pathology (C.L.), Portuguese Institute of Oncology, Porto Center, 4200-072 Porto, Portugal; Center for Investigation of Molecular
Pathobiology (M.Mo., B.C., V.L.) and Department of Endocrinology (V.L.), Portuguese Institute of Oncology, Lisbon Center, 1099-023 Lisbon, Portugal; Center for the Study of Chronic
Diseases (M.Mo., B.C., V.L.), Faculty ofMedical Sciences, University of Lisbon, 1099-085 Lisbon, Portugal; Department of Pathology (J.M.C.-T.), Clinical University Hospital, ServicioGallego
de Salud - SERGAS, Medical Faculty, University of Santiago de Compostela, 15705 Santiago de Compostela, Spain; and Department of Pathology (M.S.-S.), Hospital S. João, 4200-319
Porto, Portugal
doi: 10.1210/jc.2013-3734 jcem.endojournals.org E755
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 12 January 2015. at 10:36 For personal use only. No other uses without permission. . All rights reserved.
and 27 PTCs from the Chernobyl-irradiated setting that we
had previously studied (22) were also searched for the pres-
ence of TERT promoter mutations. Due to their etiopatho-
genic specificity (irradiation induced tumors) and lack of com-
plete clinical information, they were not included in the
subsequent clinicopathological analysis.
DNA extraction
DNA from formalin-fixed, paraffin-embedded tissues was
retrieved from 10-m sections after careful microdissection.
DNA extraction was performed using the Ultraprep tissue
DNA kit (AHN Biotechnologie) following the manufacturer’s
instructions.
PCR and Sanger sequencing
The genetic characterization of part of the tumors series re-
garding BRAF,NRAS,RET/PTC, and PAX8/PPARG had been
previously reported; mutations were screened as previously de-
scribed (23–25). To screen for TERT promoter mutations, we
analyzed the hot spots previously identified by PCR followed by
Sanger sequencing. TERT promoter mutation analysis was per-
formed with the pair of primers forward TERT, CAGCGCT-
GCCTGAAACTC; and reverse TERT, GTCCTGCCCCTT
CACCTT.Amplification of genomicDNA (25–100 ng)was per-
formed by PCR using theQIAGENmultiplex PCR kit following
the manufacturer’s instructions (further details on the amplifi-
cation will be given upon request). Sequencing reaction was per-
formedwith theABI PrismBigDye terminator kit (PerkinElmer),
and the fragments were run in an ABI prism 3100 genetic ana-
lyzer (PerkinElmer). The sequencing reaction was performed in
a forward direction, and all the detected mutations were further
validated by a new independent analysis in both strands (Sup-
plemental Figure 1).
Patients’ follow-up
Patients were treated and followed up in accordance with
international protocols available at the time. Data regarding the
number of radioiodine treatments and cumulative activity were
retrieved from hospital records, together with other therapeutic
procedures. For statistical analysis, we defined the category, ad-
ditional treatments, in which we included other treatment mo-
dalities in addition to radioiodine, including surgery, external
beam irradiation, and treatment with tyrosine kinase inhibi-
tors (Supplemental Table 2). Patients were defined as being
disease free at the end of follow-up if they had undetectable
stimulated thyroglobulin (in the absence of thyroglobulin an-
tibodies) and no imagiological evidence of disease. In the sur-
vival analysis, we have considered only deaths attributable to
the thyroid carcinoma (disease-specific mortality).
Statistical analysis
Statistical analysis was conducted with SPSS version 20.0
(SPSS Inc). The results are expressed as a percentage or mean
SD. Statistical analysis was performed both on the whole series
of follicular cell-derived thyroid carcinomas (FCDTCs) and con-
sidering thedifferent groupsof tumors.AFisher’s exact test, t test
(unpaired, two tailed), and ANOVA were used when appropri-
ate. Thepredictive value ofTERTpromotermutations andother
factors [age, gender, histologic category, extrathyroidal exten-
sion, vascular invasion, lymph node metastases, staging I–IV
(Union for International Cancer Control/American Joint Com-
mittee onCancer [AJCC]),BRAFmutations,RASmutations] for
distantmetastases and disease-free status at the end of follow-up
were assessed using univariate and multivariate logistic regres-
sion models. Survival curves were plotted by the Kaplan-Meier
method with the log-rank statistics. Multivariate survival anal-
ysis was performed using Cox regression. In the regressionmod-
els, all the variables significantly associated with the specified
outcome in the univariate model were included in the multivar-
iate analysis. Mortality was expressed as a percentage and rate
per person-year, the latter obtained dividing the number of thy-
roid cancer-specific deaths by the total follow-up time. Results
were considered statistically significant at P  .05.
Results
TERT promoter mutations were not detected in normal
parenchyma (n  30) or in benign lesions (n  81), such
asanodular goiter (hyperplastic lesions), lymphocytic thy-
roiditis, or follicular adenomas. TERT promoter muta-
tions were also not detected in medullary thyroid carci-
nomas (n  28) or in any of the 39 tumors from the
Chernobyl series (Supplemental Table 1).
TERT promoter mutations were detected in 58
FCDTCs. The mutations were detected in 25 PTCs
(7.5%), 12 FTCs (17.1%), nine poorly differentiated thy-
roid carcinomas (PDTCs; 29.0%), and 12 anaplastic thy-
roid carcinomas (ATCs; 33.3%) (Table 1). In differenti-
ated thyroid carcinomas (DTCs), the overall prevalence of
TERT promoter mutations was 9.2%. TERT promoter
mutations were slightly more frequent in conventional
PTCs (8.3%) than in cases of follicular variant of PTCs
(6.8%).All PTCsandFTCswithoncocytic features aswell
as tall-cell PTCs and Warthin-like PTCs did not harbor
TERT promoter mutations (Supplemental Table 1).Most
of the mutated cases (48 of 58) presented the 124GA
mutation and the remaining 10 cases presented the146
GA.
BecauseTERT promotermutations were only detected
in FCDTCs, the subsequent clinicopathological analysis
was restricted to these tumors (Table 1).
Relationship between TERT mutation and
clinicopathological features
In the group of patients with DTCs, the presence of
TERT promoter mutations was significantly associated
with older age (P .001) and larger tumor size (P .002)
(Table 2). Patients with tumors harboring TERT muta-
tions had more distant metastases (P  .001) and higher
stage (P .001). No association was found with the pres-
ence of vascular invasion, extrathyroidal extension, or
lymph node metastases.
A regression model was performed for factors associ-
ated with distant metastases in DTCs (Table 3). A total of
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44 patients (15.0%) with DTCs had distant metastases
detected during follow-up; the metastases were located in
the lung (n  28), bone (n  8), lung and bone (n  6),
brain (n  1), and lung and kidney (n  1). TERT pro-
motermutations [odds ratio (OR) 5.36;P .001], gender
(OR 2.31; P .02), tumor size (OR 1.28; P .009), and
vascular invasion (OR 3.94; P  .001) were associated
with distant metastases. TERT promoter mutations were
found to be a predictor of distantmetastases irrespectively
of gender and vascular invasion. When all the features
associatedwith distant metastases in the univariate model
were introduced in the multivariate regression, vascular
invasion became the only independent predictive factor of
distant metastases.
In patients with PTCs, the presence of TERT promoter
mutations was associated with older age (P .001), larger
tumor size (P .005), and higher stage (P .02) (Table 2).
Although patients with TERTmutation-positive PTCs had
distant metastases more frequently than patients harboring
TERT mutation-negative PTCs (27.8% vs 14.7%, respec-
tively), the differencewas not statistically significant (P .07).
In patients with FTCs, the presence of TERT promoter
mutations was associated with older age (P  .004),
higher stage (P .007), and distantmetastases (P .001).
In patients with PDTCs and ATCs, the presence of
TERT promoter mutations was associated with older age
(P  .003) and female gender (P  .02).
Taken BRAF and RAS together, 60.3% of TERT-mu-
tated tumors were also mutated for BRAF or RAS. In
PTCs, therewasa significant associationbetween thepres-
ence of TERT promoter mutations and the presence of
BRAFmutation (P .008) (Table 2). TheBRAFmutation
was not associated with increased lymph node or distant
metastases orwith patients’ outcome (survival) (see Figure
2H). In patients with TERT-mutated tumors, the coexis-
tence of BRAF mutations was not associated with more
aggressive clinicopathological features or worse outcome
(Supplemental Table 3 and Supplemental Figure 2). No
associationswere found concerningRASmutated tumors.
None of the cases presenting RET/PTC (12 of 75) or
PAX8/PPARG rearrangement (5 of 62) had TERT pro-
moter mutations.
Relationship between TERT promoter mutations,
clinicopathological features, and outcome
Mean follow-up time (SD) of the patients was 7.8
5.8 years (range 0.1–38.9 y). The total follow-up for the
whole of FCDTC patients was 2967.5 person-years,
Table 1. Epidemiological, Histological, and Clinical Data of Patients With FCDTCs Included in the Study
Total PTC FTC PDTC ATC
Total number 469 332 70 31 36
Age at diagnosis, y, n 469 332 70 31 36
Mean, y 48.2  16.9 44.8  15.6 51.8  16.4 53.2  18.4 68.7  10.4
45 211 (45.0) 178 (53.6) 23 (32.9) 8 (25.8) 2 (5.6)
45 258 (55.0) 154 (46.4) 47 (67.1) 23 (74.2) 34 (94.4)
Gender, n 459 327 68 29 35
Female 342 (74.5) 254 (77.7) 50 (73.5) 16 (55.2) 22 (62.9)
Male 117 (25.5) 73 (22.3) 18 (26.5) 13 (44.8) 13 (37.1)
Tumor size, cm, n 418 315 61 26 16
2a 151 (36.1) 142 (45.0) 7 (11.5) 2 (7.7) 0
2–4 161 (38.5) 129 (41.0) 23 (37.7) 7 (26.9) 2 (12.5)
4 106 (25.4) 44 (14.0) 31 (50.8) 17 (65.4) 14 (87.5)
Extrathyroidal extension, n 373 268 49 20 36
Present 231 (61.9) 176 (65.7) 8 (16.3) 12 (60.0) 35 (97.2)
Vascular invasion, n 325 257 53 8 7
Present 157 (48.3) 103 (40.1) 39 (73.6) 8 (100.0) 7 (100.0)
Lymph node metastasis, n 391 298 47 24 22
Present 234 (59.8) 202 (67.8) 8 (17.0) 14 (58.3) 10 (45.5)
Distant metastasis, n 337 263 31 20 23
Present 76 (22.6) 36 (13.7) 8 (25.8) 14 (70.0) 18 (78.3)
Stage (sixth UICC/AJCC), n 310 225 29 20 36
I 134 (43.2) 124 (55.1) 8 (27.6) 2 (10.0) 0
II 36 (11.6) 25 (11.1) 8 (27.6) 3 (15.0) 0
III 45 (14.5) 36 (16.0) 5 (17.2) 4 (20.0) 0
IV 95 (30.7) 40 (17.8) 8 (27.6) 11 (55.0) 36 (100.0)
TERT promoter, n 469 332 70 31 36
Wild-type 411 (87.6) 307 (92.5) 58 (82.9) 22 (71.0) 24 (66.7)
Mutation 58 (12.4) 25 (7.5) 12 (17.1) 9 (29.0) 12 (33.3)
Abbreviations: n, number of patients with available data for each feature; UICC, Union for International Cancer Control. Numbers in parentheses
represent percentages within each category.
a Number of microcarcinomas (1.0 cm): total, 47 (11.2%); PTC, 43 (13.7%); FTC, 4 (6.6%); PDTC, 0, ATC, 0.
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Table 2. Summary of Clinicopathological and Molecular Associations With TERT Promoter Mutations in Thyroid
Cancers
Tumor Type All Patients TERT Wild Type TERT Mutated P Value
DTCs (n  402)
Clinicopathological
Age at diagnosis, y (n  402) 46.0  16.0 44.5  15.6 60.2  12.7 <.001
Gender (n  395)
Female 304 (77.0) 278 (77.7) 26 (70.3) NS (.31)
Male 91 (23.0) 80 (22.3) 11 (29.7)
Mean tumor size, cm (n  376) 2.7  1.9 2.6  1.8 3.6  2.3 .002
Extrathyroidal extension (n  317)a
Present 184 (58.0) 167 (57.4) 17 (65.4) NS (.43)
Vascular invasion (n  310)b
Present 142 (45.8) 129 (45.4) 13 (50.0) NS (.65)
LN metastases (n  345)
Present 210 (60.9) 189 (61.0) 21 (60.0) NS (.91)
Distant metastases (n  294)
Present 44 (15.0) 34 (12.5) 10 (43.5) <.001
Stage (n  254)
I 132 (52.0) 129 (55.1) 3 (15.0) <.001
II 33 (13.0) 31 (13.3) 2 (10.0)
III 41 (16.1) 37 (15.8) 4 (20.0)
IV 48 (18.9) 37 (15.8) 11 (55.0)
Other genetic alterations
BRAF mutation (n  357) 148 (41.5) 130 (40.2) 18 (52.9) NS (.15)
NRAS mutation (n  365) 29 (7.9) 24 (7.3) 5 (14.3) NS (.15)
PTCs (n  332)
Clinicopathological
Age at diagnosis, y (n  332) 44.8  15.6 43.6  15.3 58.4  13.2 <.001
Gender (n  327)
Female 254 (77.7) 237 (78.5) 17 (68.0) NS (.23)
Male 73 (22.3) 65 (21.5) 8 (32.0)
Mean tumor size, cm (n  315) 2.4  1.5 2.3  1.4 3.2  2.2 .005
Extrathyroidal extension (n  268)a
Present 176 (65.7) 162 (64.8) 14 (77.8) NS (.26)
Vascular invasion (n  257)b
Present 103 (40.1) 98 (40.7) 5 (31.3) NS (.46)
LN metastases (n  298)
Present 202 (67.8) 184 (66.9) 18 (78.3) NS (.26)
Distant metastases (n  263)
Present 36 (13.7) 31 (14.7) 5 (27.8) NS (.07)
Stage (n  225)
I 124 (55.1) 121 (57.3) 3 (21.4) .02
II 25 (11.1) 24 (11.4) 1 (7.1)
III 36 (16.0) 32 (15.2) 4 (28.6)
IV 40 (17.8) 34 (16.1) 6 (42.9)
Other genetic alterations
BRAF mutation (n  301) 148 (49.2) 130 (46.9) 18 (75.0) .008
NRAS mutation (n  301) 15 (5.0) 14 (5.1) 1 (4.2) NS (.85)
FTCs (n  70)
Clinicopathological
Age at diagnosis, y (n  70) 51.8  16.4 49.3  16.3 63.8  11.0 .004
Gender (n  68)
Female 50 (73.5) 41 (73.2) 9 (75.0) NS (.90)
Male 18 (26.5) 15 (26.8) 3 (25.0)
Mean tumor size, cm (n  61) 4.4  2.6 4.4  2.6 4.4  2.5 NS (.96)
Extrathyroidal extension (n  49)a
Present 8 (16.3) 5 (12.2) 3 (37.5) NS (.08)
Vascular invasion (n  53)b
Present 39 (73.6) 31 (72.1) 8 (80.0) NS (.61)
LN metastases (n  47)
Present 8 (17.0) 5 (14.3) 3 (25.0) NS (.39)
(Continued)
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2760.8 person-years for DTC patients, 2342.9 person-
years for PTC patients, and 417.9 person-years for FTC
patients.
Patients with TERT promoter-mutated DTCs were
submittedtomoreradioiodinetreatments (2.71.8vs1.8
1.2;P .009)with higher cumulative doses (15.8 12.4 vs
9.0 8.1 GBq; P .004) as well as to more treatment mo-
dalities of other types (2.6  2.5 vs 1.1  1.5; P  .001)
(Supplemental Table 2). A similar analysis was not per-
formed for PDTCs andATCsdue to the heterogeneity of the
therapeutic management of these two groups of patients.
At the end of follow-up, patients with DTCs harboring
TERT-mutated tumors were more prone to have persis-
tent disease (OR 5.10; P  .001) (Table 3). Male gender
(OR 2.10; P .04) and lymph nodemetastases (OR 1.95;
P  .04) were other factors associated with disease per-
sistence. In the multivariate model, TERT promoter mu-
tations were independent predictors of persistent disease
at the end of follow-up.
During follow-up, the overall disease-specificmortality
was 11.7% in FCDTCs, 2.2% in DTCs, and 1.8% in the
group of patients with PTCs (Table 4). The disease-spe-
cific mortality rate was 14.83 per 1000 person-years in
FCDTCs, 2.53 per 1000 person-years in DTCs, and 2.13
per 1000 person-years in PTCs.
TheKaplan-Meier survival analysis showed that thepres-
ence of TERT promoter mutations was associated with in-
creased disease-specific mortality in DTCs (log rank P 
.001), PTCs (log rank P  .001), and FTCs (log rank P 
.001) (Figure 1 and Table 4). Age at diagnosis and the pres-
Table 2. Continued
Tumor Type All Patients TERT Wild Type TERT Mutated P Value
Distant metastases (n  31)
Present 8 (25.8) 3 (11.5) 5 (100.0) <.001
Stage (n  29)
I 8 (27.6) 8 (34.8) 0 .007
II 8 (27.6) 7 (30.4) 1 (16.7)
III 5 (17.2) 5 (21.7) 0
IV 8 (27.6) 3 (13.1) 5 (83.3)
Other genetic alterations
BRAF mutation (n  56) 0 0 0 c
NRAS mutation (n  64) 14 (21.9) 10 (18.9) 4 (36.4) NS (0.20)
Undifferentiated thyroid carcinomas (poorly
differentiated  anaplastic) (n  67)
Clinicopathological
Age at diagnosis, y (n  67) 61.5  16.2 58.3  17.6 68.7  9.6 .003
Gender (n  64)
Female 38 (59.4) 22 (50.0) 16 (80.0) .02
Male 26 (40.6) 22 (50.0) 4 (20.0)
Mean tumor size, cm (n  42) 6.5  3.2 6.3  3.4 6.8  2.9 NS (.62)
Extrathyroidal extension (n  56)a
Present 47 (83.9) 32 (82.1) 15 (88.2) NS (.56)
Vascular invasion (n  15)b
Present 15 (100.0) 11 (100.0) 4 (100.0) c
LN metastases (n  46)
Present 24 (52.2) 16 (57.1) 8 (44.4) NS (.40)
Distant metastases (n  43)
Present 32 (74.4) 19 (70.4) 13 (81.3) NS (.43)
Stage (n  56)
I 2 (3.6) 2 (5.3) 0 NS (.39)
II 3 (5.4) 3 (7.9) 0
III 4 (7.1) 2 (5.3) 2 (11.1)
IV 47 (83.9) 31 (81.5) 16 (88.9)
Other genetic alterations
BRAF mutation (n  65) 10 (15.4) 6 (13.6) 4 (19.0) NS (0.57)
NRAS mutation (n  61) 17 (27.9) 9 (22.5) 8 (38.1) NS (0.20)
Abbreviations: LN, lymph node; n, number of patients with available data for each feature; NS, not significant. Numbers in parentheses represent
percentages within each category. Bold values indicate the result was statistically significant.
a Extrathyroidal extension was defined as having disease extending beyond the thyroid capsule, including either microscopic or macroscopic invasion.
b Vascular invasion was defined as the presence of intravascular tumor cells either covered by endothelium or associated with thrombus, affecting
lymphatic or blood vessels within or beyond the tumor capsule.
c No statistics were computed due to constant numbers of one feature.
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ence of distantmetastaseswere the other clinicopathological
features significantly associated with patients’ survival (Fig-
ure 2).
In the Cox regression analysis, the hazard ratio (HR)
formortality fromDTC inpatients harboring tumorswith
TERT promoter mutation was 19.42 [95% confidence
interval (CI) 4.30–87.64]; after adjustment for age at di-
agnosis and gender, the HR was 10.35 (95% CI 2.01–
53.24). In the subgroup of patients with PTCswithTERT
promotermutations, theHR for disease-specificmortality
was 11.63 (95%CI 1.93–70.15); after adjustment for age
at diagnosis and gender, theHRwas23.81 (95%CI1.36–
415.76). The low number of deaths in the group of pa-
tients with FTCs precluded a similar regression analysis.
Table 3. Predictive Factors for Distant Metastases and Disease Persistence at the End of Follow-Up in Differentiated
Thyroid Carcinomas
Distant Metastases (n  294) Persistent Disease (n  211)
Presence
(%)
Univariate Analysis Multivariate Analysis
Presence
(%)
Univariate Analysis Multivariate Analysis
OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value
Total 44 (15.0) 58 (27.5)
Age, y
45 17 (11.5) 1 (Referent) NS 25 (22.9) 1 (Referent) NS
45 27 (18.5) 1.75 (0.91–3.37) (.09) 33 (32.4) 1.61 (0.87–2.96) (.13)
Gender
Female 28 (12.4) 1 .02 1 .03 42 (24.9) 1 .04 1 .03
Male 16 (24.6) 2.31 (1.16–4.60) 2.32 (1.10–4.90) 16 (41.0) 2.10 (1.02–4.35) 2.46 (1.11–5.47)
Tumor sizea 1.28 (1.07–1.54) .009 1.18 (0.97–1.44) .10 1.18 (0.97–1.43) NS (.10)
Extrathyroidal extension
No 14 (15.1) 1 NS 22 (24.4) 1 NS
Yes 22 (14.3) 0.94 (0.46–1.94) (.87) 28 (35.9) 1.73 (0.89–3.27) (.11)
Vascular invasion
No 10 (7.2) 1 .001 b 16 (20.0) 1 NS
Yes 22 (23.4) 3.94 (1.77–8.78) 22 (32.8) 1.96 (0.93–4.13) (.08)
Lymph node metastases
N0/Nx 17 (17.9) 1 NS 21 (23.3) 1 .04 1 .03
N1 27 (15.7) 0.85 (0.44–1.66) (.64) 35 (37.2) 1.95 (1.03–3.71) 2.16 (1.10–4.25)
BRAFc
wt 21 (17.2) 1 NS 20 (22.7) 1 NS
V600E 14 (12.1) 0.66 (0.32–1.37) (0.26) 26 (37.1) 2.00 (1.00–4.03) (.05)
TERT
wt 34 (12.5) 1 .001 1 .002 48 (24.6) 1 .001 1 .007
mut 10 (43.5) 5.36 (2.18–13.18) 4.60 (1.73–12.21) 10 (62.5) 5.10 (1.76–14.78) 4.68 (1.54–14.27)
Abbreviations: mut, mutated; n, number of patients with available data for each feature; NS, not significant; wt, wild type. Bold values indicate the
result was statistically significant.
a Tumor size was included in the model as a continuous variable.
b Vascular invasion was not considered in the multivariate model displayed in the table. The OR of TERT promoter mutations for distant metastases
adjusted for gender was 5.61 (2.24–16.06) (P  .001); the OR of TERT promoter mutations adjusted for tumor size was 4.30 (1.66–11.13) (P 
.003); the OR of TERT promoter mutations adjusted for vascular invasion was 3.54 (1.06–11.82) (P  .04); the OR of TERT promoter mutations
adjusted for vascular invasion and gender was 3.51 (1.05–11.72) (P  .04). When all the features associated with distant metastases in the
univariate model (gender, tumor size, TERT mutational status, and vascular invasion) were included in the multivariate model, vascular invasion was
the only independent predictor of distant metastases, with an OR adjusted for age, tumor size, gender, and TERT of 3.38 (1.42–8.04).
c BRAF analysis was performed only in the group of PTC.
Table 4. Thyroid Cancer-Specific Mortality and Hazard Ratios for Patients With TERT wt vs TERT Mutated Tumors
Type of
Cancer
Mortality, n , %
Mortality
Rate (Deaths
per 1000
Person-Years) Hazard Ratio (95% CI)
Overall TERT wt
TERT
Mutated
P
Value
a
TERT
wt
TERT
Mutated Unadjusted
P
Value Adjustedb
P
Value
DTC 7/323 (2.2) 3/298 (1.0) 4/25 (16.0) .001 1.17 21.17 19.42 (4.30–87.64) .001 10.35 (2.01–53.24) .005
PTC 5/284 (1.8) 3/265 (1.1) 2/19 (10.5) .001 1.36 13.64 11.63 (1.93–70.15) .007 23.81 (1.36–415.76) .03
FTC 2/70 (2.8) 0/58 2/12 (16.7) .001 0 47.23
c c c c
Abbreviations: mut, mutated; wt, wild type.
a Log-rank P values.
b Adjusted for age and gender (Cox regression).
c Due to the low numbers, a regression analysis was not performed for FTC patients.
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Discussion
In the present study, we show that TERT promoter mu-
tations are an indicator of tumor aggressiveness in DTCs,
being associated with distant metastases, worse response
to treatment, and poor outcome.
TERT promoter mutations were present in 12.4%of the
FCDTC tumors, being detected in PTCs and FTCs (7.5%
and 17.1%, respectively), PDTCs and ATCs (29.0% and
33.3%, respectively). The frequencies of TERT promoter
mutations in DTCs are similar to those recently reported by
Liu et al (19) and lower than those reported by Landa et al
(20) and Liu et al (26).TERT promoter mutations were not
detected in normal thyroid or in benign lesions, such as nod-
ular goiter, adenoma, or thyroiditis, or inmedullary thyroid
carcinomas.Thesenegative findings fitwithprevious reports
(15,19,20).NoTERTpromotermutationsweredetected in
benign or malignant tumors from Chernobyl-irradiated pa-
tients, suggesting that irradiation is not a strong etiological
factor for the occurrence of such mutations.
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Figure 1. Kaplan-Meier survival curves of thyroid carcinoma-specific survival by TERT mutation status representing the whole follicular cell-derived
thyroid carcinoma series (A), the group of patients with differentiated thyroid carcinoma (B), the subgroups of patients with PTCs (C), and the
subgroup of patients with FTCs (D). TERT mut, TERT promoter mutation; TERT wt, TERT promoter wild type.
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WedidnotdetectTERTpromotermutations inanyof the
carcinomas displaying oncocytic features (Supplemental Ta-
ble 1). The absence ofmutationsmay reflect the small size of
theseries regardingoncocyticvariantofPTCs, tall-cellPTCs,
and Warthin-like PTCs. This does not hold true, however,
regarding FTCs in which TERT promoter mutations were
notdetectedinanyofthe27oncocyticcases (0%), incontrast
to their presence in12of the43conventional FTCs (27.9%).
Wedonotknowhowtoexplain this finding,whichhas tobe
confirmed in larger series, namely of oncocytic PTCs, butwe
believe it contributes to reinforce the assumption that onco-
cytic tumors of the thyroid differ from their nononcocytic
counterparts with regard to several genetic and metabolic
pathways (25, 27).
The relatively low number of microcarcinomas
(11.2%; Table 1), all negative for TERT promoter muta-
tions, and the higher percentage of cases with distant me-
tastases (15%ofDTCs) in comparisonwith data reported
in some recent series (28, 29) support the assumption that
one may be dealing in the present study with higher-stage
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Figure 2. Kaplan-Meier survival curves of DTC-specific survival according to the different clinicopathological and molecular features: gender (A), age (B),
tumor size (C), extrathyroidal extension (D), vascular invasion (E), lymph node metastases (F), distant metastases (G), and BRAF status in PTCs (H).
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cases referred to academic centers. Further studies includ-
ing lower-risk patients are necessary to establish a more
accurate evaluation of the frequency of TERT promoter
mutations in the different histotypes of FCDTCs.
InDTCs, the presence ofTERT promotermutationswas
associatedwith older age at diagnosis, larger tumors, higher
frequency of distant metastases, and higher tumor stage.
These results are in linewith previous reports indicating that
TERTpromotermutationsweremore prevalent in histolog-
ical categories of thyroid carcinomas classically associated
withmoreaggressive clinicalbehavior (15,19,20).Themost
important added value of the present study is that we found
evidence showing that patients with TERTmutated tumors
had decreased survival when compared with patients with
tumors harboring wild-type TERT and, moreover, that this
holds true for the whole DTC series as well as for PTCs and
FTCs independently. The usefulness of TERTmutations as
a prognostic marker is particularly relevant in DTCs due to
the combination of two main reasons: only a small percent-
age of such carcinomas behave aggressively and may turn
ultimately lethal, and there is a lack of good prognostic in-
dicators in this setting.
TERT promoter mutations were more prevalent in
PDTCs (29.0%) and ATCs (33.3%) than in DTCs. Al-
thoughwe did not find an association betweenTERT pro-
moter mutations and mortality in this subset of less dif-
ferentiated tumors (data not shown), the dismal outcome
of most patients with poorly differentiated/undifferenti-
ated carcinomas and their aggressive clinicopathological
characteristics raises doubts about theprognostic utility of
molecular markers, such as TERT promoter mutations,
froma clinical standpoint. Furthermore, the small number
of patients in each of the two categories does not allow a
definitive conclusion on this issue.We also believe that the
predictive value ofTERT promotermutations for disease-
specificmortality in patientswith FTCs should be clarified
in larger series because we acknowledge the small number
of events that occurred in our series due to the relatively
low number of FTCs patients with appropriate follow-up.
Although the overall prognosis of patients with DTCs is
usually good, with a 10-year survival rate higher than 85%
inmost series (30), theoutcomeofolderpatientswithdistant
metastases is guarded, with a 5-year survival of approxi-
mately 30%–40% (31). Due to the clinical relevance of dis-
tantmetastases, we performed amultivariate logistic regres-
sionevaluatingtheclinicopathologicalandmolecular factors
associated with distant metastasization. The presence of
TERT promoter mutations was a significant predictor of
distant metastases after adjusting for gender, tumor size, or
vascular invasion, independently. When all the features as-
sociated with distant metastases in the univariated model
(gender, tumor size, vascular invasion, and TERT muta-
tional status) were included in the regression, vascular inva-
sion became the only independent predictor. From the clin-
ical standpoint, vascular invasion is information available
only after surgery and all the others [age, gender, tumor size
(estimated by ultrasound), and TERT mutational status (if
feasible in fine needle aspiration cytology)] may in the near
future be available for physicians before surgery, allowing a
better risk stratification before the first treatment approach.
For this reason, we decided to present the results of themul-
tivariate model with andwithout the input of vascular inva-
sion (Table 3).
The association ofTERT promoter mutations with de-
creased survival in DTCs was kept irrespectively of age at
diagnosis and gender. In addition to TERT promoter mu-
tations and distant metastases, age at diagnosis was the
only factor significantly associated with decreased sur-
vival in the present study. Age at diagnosis is a well-es-
tablishedpredictorofmortality inDTCs, and this hasbeen
recognizedby theUnion for InternationalCancerControl/
AJCC, setting age at diagnosis as a major determinant in
the staging system (32). Even thoughmale gender was not
associated with decreased survival in our study, a large
population-based cancer registry (Surveillance, Epidemi-
ology and End-Results) showed that male gender may be
associated with increased mortality (33). This finding fits
with our results showing that male gender was signifi-
cantly associated with distant metastases and disease per-
sistence at the end of follow-up. These were the reasons
that we decided to adjust the HR for both age at diagnosis
and gender. The independent association of TERT pro-
moter mutations with decreased survival holds true if we
adjust the HR either for age at diagnosis (data not shown)
or for both age at diagnosis and gender (Table 4).
Liu et al (26) recently published a report studying the fre-
quency of TERT promoter mutations in a series of 107
FCDTCs (51 PTCs, 36 FTCs, and 20 ATCs) and its rela-
tionship with older age and shorter telomeres. The authors
also found an association between TERT promoter muta-
tionsanddistantmetastasesaswellasshorterdisease-specific
survival in thewhole FCDTCseries and in PTCs. The results
of this study fit in general with our findings. However, it
should be emphasized that the report of Liu et al (26) was
conducted in a small group of patients with extremely ag-
gressiveDTCs(51PTCsand36FTCs,withadisease-specific
mortality of 24.1%). At variancewith the study by Liu et al,
thedisease-specificmortality in thepresent study is similar to
those reported in most of the large recent series (34, 35).
Furthermore, our study allowed a regression analysis in
whichtheeffectofTERTmutational statusonsurvival could
be determined and adjusted for age at diagnosis and gender.
Taken together, we may say that, although performed in
different populations, both studies indicate that TERT pro-
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motermutationsmay serve as amarker of aggressive disease
and poor outcome in DTCs.
Our data show that DTCpatients withTERT promoter-
mutated tumors were less prone to be free of disease at the
end of follow-up and were submitted to more radioiodine
treatments with higher cumulative activities as well as to a
greater number of other treatment modalities. Combining
this informationwith theworse outcome of the patients, it is
likely that, in the future, TERT promoter mutational status
maybeused to individualize treatment decisions, namely the
type of surgery (if the molecular study proves to be feasible
in fine needle aspiration cytology), the decision to perform
radioiodineablation, and theamountof 131I toadminister to
patients. The latter issue is particularly relevant due to the
current trend to reduce the number of patients submitted to
radioiodine ablation and to use lower doses (36–38). Inter-
nationalconsensusandguidelinesmayalsotake intoaccount
TERT promoter mutational status to establish the best fol-
low-up strategy for the individual patient.
Considering thatDNAorRNAofTERThasbeenusedas
vaccines to induce T-helper cells and specific cytotoxic T
lymphocyte responses against TERT-positive tumors (39,
40), it seems possible that, in the future, TERT-based im-
munotherapiesmay be tailored for patientswithTERT-mu-
tated carcinomas because these tumors carry a poor out-
come, possibly because of a worse response to current
therapies. Further studies are necessary to address this issue.
All the institutions involved in the present study fol-
lowed international guidelines, but there were discrepan-
cies regarding prophylactic central lymphnode dissection.
Taking into consideration that the role of such dissection
is currently under debate and the existing differences from
institution to institution of the present study, we did not
investigate the implications of prophylactic lymph node
dissection on the outcome.
TERT mutations were associated with BRAF muta-
tions, highlighting the coexistence of activation of BRAF
andofTERT genes, previously reported inmelanoma (16)
and thyroid (15). Horn et al (16) advanced that the mu-
tation creates newly consensus binding sites for TCF sub-
family transcription factors (Elk1 and Elk4) that can be
activated byBRAF. Both in thyroid carcinoma and inmel-
anoma, it seems that a background status of activated
BRAF enhances the effects of TERT promoter mutation.
Our previous results in TERTmRNA expression corrob-
orated this assumption showing an increased TERT ex-
pression in tumors harboring BRAF and TERTmutation
(15). However, the concurrence or coexistence in the cur-
rent study of TERT and BRAF mutations was not asso-
ciatedwith increasedaggressiveness andworseoutcome in
comparison with the presence of TERT mutations alone
(SupplementalTable 3 andSupplemental Figure 2).None-
theless, these results should be viewedwith caution due to
the low number of patients in each of the two groups.
It remains to be fully clarified the biological meaning of
the association betweenTERT promoter mutations and the
metastatic nature of thyroid tumors. Being one of the hall-
marks of cancer and enabling replicative immortality of can-
cer cells, TERT activation appears to be independent of the
tumormicroenvironment because there is no substantive ev-
idence for stromal contributions to telomere stabilization in
cancer cells (41). Our findings suggest that a link between
telomerase activity and metastatic capacity may exist. We
can speculate that this link may be inherent to the extended
survival ofTERT-mutated cells during the circulation phase
and/or the homing in distant places, rather than to the in-
creased invasiveness of such cells, but the discussion of this
issue is beyond the scope of the present study.
We conclude that TERT promoter mutations are an
indicator of clinical aggressiveness of follicular cell-de-
rived thyroid carcinomas, being associated with distant
metastases, worse response to treatment, and poor out-
come. The detection of such mutations appears to be, per
se, a promising prognostic indicator in DTCs and PTCs.
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